VKTXViking Therapeutics, Inc.
$28.50+12% 1Y
$28.50
$24.9752 weeks$40.87
The financials
Viking Therapeutics, Inc. by the numbers
Viking Therapeutics, Inc. (VKTX) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $128M. For the full year FY2025, revenue was $0 and net income −$360M. The next results filing is expected around Oct 21, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$133M | −$75M | n/a |
| Net income | −$128M | −$66M | n/a |
| Diluted EPS | −$1.10 | −$0.58 | n/a |
On our screens:Most shorted stocks